Date: 2013-03-20
Type of information: Initiation of the trial
phase: 1b
Announcement: initiation of the study
Company: Circassia (UK)
Product: PAP-1
Action
mechanism: PAP-1 is a selective Kv1.3 inhibitor, and has achieved impressive results in pre-clinical models of psoriasis when applied topically. The treatment is a highly specific immunosuppressant, acting on effector memory T-cells while leaving naïve and central memory T-cells intact.
Disease: psoriasis
Therapeutic area: Autoimmune diseases – Dermatological diseases
Country: Germany
Trial
details: The study will include 24 patients with mild to moderate psoriasis. During the trial, investigators will apply five different ointments to separate areas of a single psoriasis plaque on each patient. Each ointment will contain one of three different concentrations of PAP-1, calcipotriol or placebo. Following 10 days of treatment, the study will assess the reduction in plaque thickness from pre-therapy levels at each of the treated sites. Investigators will also use a plaque scoring system to evaluate clinical improvements in patients’ psoriasis.
Latest
news: * On March 20, 2013, Circassia has announced that it has initiated a proof-of-principle clinical study of its novel topical psoriasis treatment, PAP-1. The phase Ib trial is designed to compare the efficacy of PAP-1 with the marketed psoriasis treatment, calcipotriol, and placebo. The study is underway in Germany.
